# Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

> **NCT05911724** · — · COMPLETED · sponsor: **Damanhour University** · enrollment: 180 (actual)

## Conditions studied

- Stable Angina
- Heart Failure

## Interventions

- **OTHER:** Group I Healthy
- **DRUG:** CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
- **DRUG:** HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

## Key facts

- **NCT ID:** NCT05911724
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-30
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911724, "Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05911724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*